Published online Nov 28, 2024. doi: 10.3748/wjg.v30.i44.4759
Revised: September 22, 2024
Accepted: October 22, 2024
Published online: November 28, 2024
Processing time: 93 Days and 17.6 Hours
In this letter, we comment on the article by López-Gómez et al, which explores the prevalence of Helicobacter pylori (H. pylori) infection among patients with esophageal carcinoma (EC) in a cohort of Spain population. The relationship between H. pylori infection and EC is very complex. Previous research results are often contradictory due to the influence of dietary habits, age, region, and other factors. López-Gómez et al reported a very low prevalence of previous H. pylori infection in their cohort of patients with EC, and most of them had previously received or concomitantly received proton pump inhibitors treatment. These results are similar to previous results, which suggest that H. pylori infection is related to the low incidence of EC. Therefore, this study may provide a direction for preventing EC and eradicating H. pylori in Spain.
Core Tip: López-Gómez et al provided evidence of a very low prevalence of previous Helicobacter pylori infection in a Spanish cohort of patients with esophageal carcinoma, and most of those patients had previously received or concomitantly received proton pump inhibitors treatment. However, more studies (such as prospective studies or Mendelian randomization studies) are still needed to confirm the causal relationship between them in the future.
- Citation: Zhang C, Ouyang YW, Li ZT. Role of Helicobacter pylori in esophageal carcinogenesis: Friend or foe? World J Gastroenterol 2024; 30(44): 4759-4762
- URL: https://www.wjgnet.com/1007-9327/full/v30/i44/4759.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i44.4759
Esophageal carcinoma (EC) is a malignancy that affects the esophagus and mainly consists of four types: Esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC), undifferentiated carcinoma, and other types. According to GLOBOCAN 2020 data, EC is the eighth most common cancer worldwide, with an estimated 604100 new cases and 544076 deaths per year[1]. In terms of clinical manifestations, the early symptoms of EC are not obvious, but with the development of the disease, patients can experience progressive dysphagia, swallowing pain, reflux, and vomiting, which seriously affect their quality of life[2,3]. In terms of treatment methods, the main treatment methods for esophageal cancer include endoscopic therapy (endoscopic mucosal resection, endoscopic submucosal dissection, etc.), surgery, chemotherapy, radiotherapy, immunotherapy, targeted drug therapy, and biological therapy. Although early EC can be cured through endoscopic therapy, the treatment of advanced esophageal cancer is relatively difficult and expensive, which places a heavy economic burden on patients and their families. Therefore, exploring the risk factors and protective factors for esophageal cancer and the underlying mechanisms will contribute to the prevention and treatment of EC in the future.
Helicobacter pylori (H. pylori) is a gram-negative, spiral, flagellated, microaerophilic bacterium that colonizes the gastric mucosa of humans. This bacterium invades the submucosal membrane of the stomach through fecal-oral or fecal-fecal transmission, leading to gastric and duodenal diseases. In different countries, the prevalence of H. pylori ranges from approximately 34.7% to 50.8%[4]. It is a well-known pathogen involved in various gastric diseases, including chronic gastritis, peptic ulcers, mucosa-associated lymphoid tissue lymphoma, and gastric adenocarcinoma[5]. However, in addition to being a risk factor for stomach-related diseases, H. pylori may have potential protective effects on certain autoimmune diseases, such as asthma and inflammatory bowel disease[6]. Notably, the results of previous studies on the relationship between H. pylori and EC are contradictory, with some studies suggesting that H. pylori has a protective effect on EC, whereas others suggest that H. pylori has no protective effect[7-11].
Proton pump inhibitors (PPIs) are a class of medications that inhibit the hydrion ion potassium ion-ATPase in parietal cells, leading to a reduction in gastric acid secretion. These drugs are commonly used to treat various gastrointestinal disorders such as peptic ulcers, esophagitis, hyperacidity, H. pylori infection, and gastroesophageal reflux disease (GERD). However, PPIs have additional effects beyond acid suppression, which inhibits bone resorption and decreases urinary calcium excretion, potentially impacting bone health[12]. Therefore, considering the long-term use of PPIs to control GERD in clinical practice, their role in EC is also worth exploring.
Although many previous studies have investigated the relationship between H. pylori and EC, the conclusions drawn by different studies are inconsistent. In addition, the incidence of H. pylori and EC is extremely different in different regions. Here, we pay special attention to the study by López-Gómez et al[13] in the latest issue of the World Journal of Gastroenterology, analyzing the prevalence of H. pylori in EC patients from a tertiary hospital in Madrid, Spain, and discussing its possible mechanism.
The relationship between H. pylori infection and EC is very complex. Previous research results are often contradictory due to the influence of dietary habits, age, region, and other factors. Considering that the risk factors and mechanisms of EAC and ESCC are inconsistent, we discuss them separately.
Many previous meta-analyses have shown that H. pylori is associated with a reduction in the risk of EAC[7-9]. Barrett’s esophagus (BE), which can develop from GERD, can develop into EAC. A meta-analysis investigated the relationships between H. pylori and BE or GERD, and the results revealed that H. pylori was associated with a low risk of both BE and GERD[14]. These findings suggest that H. pylori may play a role in multiple stages of tumorigenesis. The underlying mechanisms may include the following aspects[15]: (1) H. pylori infection may promote gastric emptying by inhibiting ghrelin levels, thereby reducing the risk of BE and EAC; (2) Excessive secretion of gastric acid promotes the pathogenesis of GERD and BE. Atrophy of the gastric mucosa after H. pylori infection can reduce gastric acid secretion and reflux, thereby reducing the risk of EAC; (3) H. pylori can promote the apoptosis of EAC cells; (4) Eradication of H. pylori may promote the occurrence of EAC by affecting the distribution of esophageal microorganisms; and (5) H. pylori may increase the pressure on the lower esophageal sphincter by promoting gastrin secretion, thereby reducing the occurrence of GERD.
In contrast, the relationship between H. pylori and ESCC is inconclusive. Some retrospective studies have shown that H. pylori has a protective effect on ESCC[10,11]. The meta-analysis suggested that H. pylori did not have a protective effect on ESCC in the overall population [odds ratio (OR) = 0.84; 95% confidence interval (CI): 0.64-1.09], whereas the subgroup analysis suggested that H. pylori had a protective effect in the Middle East (OR = 0.34; 95%CI: 0.22-0.52) or East Asia population (OR = 0.66; 95%CI: 0.43-0.89)[7,8]. These results may be related to the inconsistent dietary habits, drinking habits and genetic factors across different regions. To date, ESCC still accounts for the vast majority of ECs. Therefore, it is necessary to study the different roles played by H. pylori in the ESCC of different regions.
López-Gómez et al[13] conducted a retrospective study that included 89 patients with EC in a Spanish hospital from February 2008 to December 2023. Among these patients, 47 (52.8%) had EAC and 37 (41.6%) had ESCC. The results revealed that there were a total of 4 cases of H. pylori infection in EC, including 3 cases in EAC (accounting for 6.3% of all EAC cases), and 1 case in ESCC (accounting for 2.7% of all ESCC cases). It is obvious that the infection rate of H. pylori in this cohort was much lower than that in the general population, whether it was EAC or ESCC. In summary, these results suggest that H. pylori may have a protective effect on EAC and ESCC in Madrid, Spain.
There are many kinds of PPIs commonly used, including lansoprazole, pantoprazole, rabeprazole, omeprazole, esomeprazole and so on. In recent years, PPIs have become one of the most commonly used drugs because of their good effects. Although short-term use is often considered safe, long-term use is associated with risks such as cancer and osteoporosis[12,16,17]. Previous studies have shown that long-term use of PPIs can increase the risk of gastric cancer and colorectal cancer while reducing the risk of cervical cancer, breast cancer, and ovarian cancer[17-19]. However, whether the use of PPIs affects the occurrence of EC remains unclear. Considering that PPI drugs can inhibit the growth of H. pylori and that H. pylori is associated with a low risk of EAC, the use of PPIs may be associated with the risk of EAC. In the study of López-Gómez et al[13], 86 (96.6%) of 89 patients with EC had used or were using PPIs, suggesting a possible correlation between PPIs and EC.
The study of López-Gómez et al[13] provided new evidence for the relationship between H. pylori infection and esophageal cancer in Spain. The abuse of PPIs may be one of the factors leading to EC. Therefore, long-term clinical use of PPIs should be treated with caution. Although many previous studies and meta-analyses have concluded that H. pylori can reduce the risk of EAC, there are no relatively reliable prospective studies. In addition, international consensus recommendations advocate for PPI therapy in patients with BE because high-quality evidence derived from randomized controlled trials indicates that PPIs play a chemo-preventative role in developing Barrett’s associated neoplasia. Considering that PPIs are commonly used drugs for BE, it is still unclear whether PPIs are the cause or result of EC. Therefore, in the future, we can use Mendelian randomization analysis or perform prospective studies to obtain more reliable conclusions. In addition, we can explore the mechanism by which H. pylori affects EC through additional animal and cell tests. Moreover, we can identify relevant targets through multi-omics analysis, providing new ideas to prevent EC in the future.
The study of López-Gómez et al[13] suggested that H. pylori infection was associated with a low risk of EC in Spain. Further study revealed that most patients with EC had used or were using PPIs, suggesting that PPIs may be associated with the occurrence of EC in this region. These results may provide new insights into the prevention and treatment of EC in Spain.
1. | Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-249. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 50630] [Cited by in F6Publishing: 54274] [Article Influence: 18091.3] [Reference Citation Analysis (156)] |
2. | Jain PK, Babu RG. Safety of endoscopic self-expanding metallic stent placement in esophageal cancer without fluoroscopy. Int Surg J. 2016;3:1757-1760. [DOI] [Cited in This Article: ] |
3. | Zang Z, Liu Y, Wang J, Liu Y, Zhang S, Zhang Y, Zhang L, Zhao D, Liu F, Chao L, Wang X, Zhang C, Song G, Zhang Z, Li Y, Yan Z, Wen Y, Ge Y, Niu C, Feng W, Nakyeyune R, Shen Y, Shao Y, Guo X, Yang A, Liu F, Wang G. Dietary patterns and severity of symptom with the risk of esophageal squamous cell carcinoma and its histological precursor lesions in China: a multicenter cross-sectional latent class analysis. BMC Cancer. 2022;22:95. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
4. | Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47:868-876. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 377] [Cited by in F6Publishing: 446] [Article Influence: 74.3] [Reference Citation Analysis (1)] |
5. | Gobert AP, Asim M, Piazuelo MB, Verriere T, Scull BP, de Sablet T, Glumac A, Lewis ND, Correa P, Peek RM Jr, Chaturvedi R, Wilson KT. Disruption of nitric oxide signaling by Helicobacter pylori results in enhanced inflammation by inhibition of heme oxygenase-1. J Immunol. 2011;187:5370-5379. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
6. | Sibony M, Jones NL. Recent advances in Helicobacter pylori pathogenesis. Curr Opin Gastroenterol. 2012;28:30-35. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis (0)] |
7. | Gao H, Li L, Zhang C, Tu J, Geng X, Wang J, Zhou X, Jing J, Pan W. Systematic Review with Meta-analysis: Association of Helicobacter pylori Infection with Esophageal Cancer. Gastroenterol Res Pract. 2019;2019:1953497. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis (0)] |
8. | Xie FJ, Zhang YP, Zheng QQ, Jin HC, Wang FL, Chen M, Shao L, Zou DH, Yu XM, Mao WM. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol. 2013;19:6098-6107. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 108] [Cited by in F6Publishing: 112] [Article Influence: 10.2] [Reference Citation Analysis (0)] |
9. | Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008;1:329-338. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 230] [Cited by in F6Publishing: 234] [Article Influence: 15.6] [Reference Citation Analysis (1)] |
10. | Wu IC, Wu DC, Yu FJ, Wang JY, Kuo CH, Yang SF, Wang CL, Wu MT. Association between Helicobacter pylori seropositivity and digestive tract cancers. World J Gastroenterol. 2009;15:5465-5471. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
11. | Wu DC, Wu IC, Lee JM, Hsu HK, Kao EL, Chou SH, Wu MT. Helicobacter pylori infection: a protective factor for esophageal squamous cell carcinoma in a Taiwanese population. Am J Gastroenterol. 2005;100:588-593. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis (0)] |
12. | McGowan B, Bennett K, Barry M. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice. Pharmacoepidemiol Drug Saf. 2010;19:763-769. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
13. | López-Gómez M, Morales M, Fuerte R, Muñoz M, Delgado-López PD, Gómez-Cerezo JF, Casado E. Prevalence of Helicobacter pylori infection among patients with esophageal carcinoma. World J Gastroenterol. 2024;30:3479-3487. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (7)] |
14. | Wang Z, Shaheen NJ, Whiteman DC, Anderson LA, Vaughan TL, Corley DA, El-Serag HB, Rubenstein JH, Thrift AP. Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol. 2018;113:1148-1155. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 37] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis (0)] |
15. | Li Y, Wei B, Xue X, Li H, Li J. Microbiome changes in esophageal cancer: implications for pathogenesis and prognosis. Cancer Biol Med. 2023;21:163-174. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
16. | Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut. 2022;71:16-24. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 67] [Cited by in F6Publishing: 47] [Article Influence: 23.5] [Reference Citation Analysis (0)] |
17. | Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67:28-35. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 266] [Cited by in F6Publishing: 309] [Article Influence: 51.5] [Reference Citation Analysis (1)] |
18. | Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sørensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007;133:755-760. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 5.5] [Reference Citation Analysis (0)] |
19. | Nguyen NTH, Huang CW, Wang CH, Lin MC, Hsu JC, Hsu MH, Iqbal U, Nguyen PA, Yang HC. Association between Proton Pump Inhibitor Use and the Risk of Female Cancers: A Nested Case-Control Study of 23 Million Individuals. Cancers (Basel). 2022;14. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |